Japan’s Chugai, Taisho To Seek Approval For Co-Developed Drug
This article was originally published in PharmAsia News
Chugai Pharmaceutical and Taisho Pharmaceutical, both of Japan, plan to submit their eledecalcitol drug for approval in the country. Phase III trials of the vitamin D derivative have been positive, besting a Teijin competitor in comparison trials for treating fractures related to osteoporosis. Chugai, majority-owned by Roche, discovered the drug and is considering foreign trials, according to a spokesman. (Click here for more
You may also be interested in...
TOKYO - Chugai Pharmaceutical signed a research agreement with a local Tokyo-based bio venture, Chiome Bioscience to deploy Chiome's Autonomously Diversifying Library system, a monoclonal antibody generation technology for developing monoclonal antibodies against various target proteins owned by Chugai, a Chugai spokesman confirmed Jan. 9
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.